Results revealed that knockdown of SMIT1 induced proliferation inhibition and apoptosis in U2932 and OCI-Ly10 cells via provoking the activation of AKT signaling, suggesting that SMIT1 may serve as a novel therapeutic target for ABC-type of DLBCL, regardless of PTEN expression status. This evidence concerns the gene PTEN and diffuse large B-cell lymphoma.